Eric J. Bow

Eric J. Bow

Auto-generated profile, based on publicly available information

Eric J. Bow

Health Sciences Centre

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2002 in Cancer
Verified
Journal Article
Open access
PDF file
EBEric J. Bow
Eric J. Bow
MLMichel Laverdière
Michel Laverdière
NLNathalie Lussier
Nathalie Lussier
CRColeman Rotstein
Coleman Rotstein
MCMary S. Cheang
Mary S. Cheang
SIStratis Ioannou
Stratis Ioannou
BACKGROUND: The overall clinical efficacy of the azoles antifungal agents and low‐dose intravenous amphotericin B for antifungal chemoprophylaxis in patients with malignant disease who have severe neutropenia remains unclear.METHODS: Randomized‐controlled trials of azoles (fluconazole, itraconazole, ketoconazole, and miconazole) or intravenous amphotericin B formulations compared with placebo/no treatment or polyene‐based controls in severely neutropenic chemotherapy recipients were evaluated using meta‐analytical techniques.RESULTS: Thirty‐eight trials that included 7014 patients (study agents, 3515 patients; control patients, 3499 patients) were analyzed. Overall, there were reductions in the use of parenteral antifungal therapy (prophylaxis success: odds ratio [OR], 0.57; 95% confidence interval [95% CI], 0.48–0.68; relative risk reduction [RRR], 19%; number requiring treatment for this outcome [NNT], 10 patients), superficial fungal infection (OR, 0.29; 95% CI, 0.20–0.43; RRR, 61%; NNT, 12 patients), invasive fungal infection (OR, 0.44; 95% CI, 0.35–0.55; RRR, 56%; NNT, 22 patients), and fungal infection‐related mortality (OR, 0.58; 95% CI, 0.41–0.82; RRR, 47%; NNT, 52 patients). Invasive aspergillosis was unaffected (OR, 1.03; 95% CI, 0.62–1.44). Although overall mortality was not reduced (OR, 0.87; 95% CI, 0.74–1.03), subgroup analyses showed reduced mortality in studies of patients who had prolonged neutropenia (OR, 0.72; 95% CI, 0.55–0.95) or who underwent hematopoietic stem cell transplantation (HSCT) (OR, 0.77; 95% CI, 0.59–0.99). The multivariate metaregression analyses identified HSCT, prolonged neutropenia, acute leukemia with prolonged neutropenia, and higher azole dose as predictors of treatment effect.CONCLUSIONS: Antifungal prophylaxis reduced morbidity, as evidenced by reductions in the use of parenteral antifungal therapy, superficial fungal infection, and invasive fungal infection, as well as reducing fungal infection‐related mortality. These effects were most pronounced in patients with malignant disease who had prolonged neutropenia and HSCT recipients. Cancer 2002;94:3230–46. © 2002 American Cancer Society.DOI 10.1002/cncr.10610

1 April 1999 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EBEric J. Bow
Eric J. Bow
MKMarilyn G. Kilpatrick
Marilyn G. Kilpatrick
JCJennifer J. Clinch
Jennifer J. Clinch
PURPOSE: To examine the safety, efficacy, costs, and impact on quality of life of venous access ports implanted at the outset of a course of intravenous cancer chemotherapy. PATIENTS AND METHODS: Adults beginning a course of intravenous chemotherapy at two university-affiliated hospitals were randomly allocated to have venous access using a surgically implanted venous access port (Port-a-Cath; Pharmacia, Canada Inc, Montreal, Québec, Canada) or using standard peripheral venous access. All accesses were documented by number, route, purpose, and procedure duration. Outcome measurements included port complications, access strategy failure, access-related anxiety and pain, quality of life (Functional Living Index–Cancer [FLI-C]), and costs. RESULTS: Port complication rates were low (0.23/1,000 days). Failure occurred in two (3.4%) of 59 port subjects and 16 (26.7%) of 60 controls (P = .0004) at a median period of 26 days after randomization (95% confidence interval, 8 to 92). Peripheral accesses in port subjects took less time, had less access-related anxiety and pain, and were less costly to perform than in controls. Allocation had no effect on FLI-C scores. Peripheral access failure correlated with allocation to the control group (P = .007), higher pain scores with intravenous (IV) starts (P = .003), and anxiety with IV starts (P = .01). Venous accessing overall in port patients was four times more costly than that in controls ($2,178/patient v $530/patient, respectively). CONCLUSION: Ports were safe and effective but had no detectable impact on functional quality of life, despite less access-related anxiety, pain, and discomfort. Because only approximately one quarter of control patients ultimately required central venous access, economic considerations suggest that port-use policies should be based upon defined criteria of need.

15 August 2006 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
EBE. J. Bow
E. J. Bow
CRC. Rotstein
C. Rotstein
GNG. A. Noskin
G. A. Noskin
MRM. Laverdiè Re
M. Laverdiè Re
ASA. P. Schwarer
A. P. Schwarer
SSS. Sanche
S. Sanche
Background. The empirical treatment of febrile, neutropenic patients with cancer requires antibacterial regimens active against both gram-positive an

2 November 2006 in Leukemia
Verified
Journal Article
Closed access
PDF file
EBE J Bow
E J Bow
JMJ B Meddings
J B Meddings